




<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b>		ATTY. DOCKET NO.: <b>39780-16182C17</b>	SERIAL NO.: <b>09/904,838</b>
		<b>APPLICANT :</b> Ashkenazi, et al.	
		<b>FILING DATE:</b> 7/13/01	<b>GROUP:</b> 1647
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<p>Ashkenazi, et al., "Novel isolated PRO polypeptides, e.g. PRO245 and PRO1868, useful for treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, cancer, neuropathies, diabetes and psoriasis", P_ACD23222; Patent: US2003064367-A1, filed July 13, 2001; Publication Date: April 3, 2003.</p>			
<p>Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ABX71541; Patent: US2002132240-A1; filed July 18, 2001; Publication Date: September 19, 2002.</p>			
<p>Ashkenazi, et al., "Novel secreted and transmembrane polypeptides for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptides, and as molecular weight markers", P_ACD20098; Patent: US2003036060-A1; filed July 12, 2001; Publication Date: February 20, 2003.</p>			
<p>Ashkenazi, et al., "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and Neurodegenerative diseases (e.g. Alzheimer's disease)", P_AAF72392; Patent: WO200104311-A1; filed February 22, 2000; Publication Date: January 18, 2001.</p>			
<p>Botstein, et al., "New antibody that binds to a PRO polypeptide, e.g. PRO187 and PRO533, useful for diagnosing and treating cancers", P_AAF60376; Patent: WO200105836-A1; filed December 20, 1999; Publication Date: January 25, 2001.</p>			
<p>Goddard, et al., "New isolated antibodies which bind to specific polypeptides used for diagnosis and treatment of neoplastic cell growth and proliferation", P AAA30056; Patent: WO200015666-A2; filed September 8, 1999; Publication Date: March 23, 2000.</p>			
<p>Botstein, et al., "Antibodies against specific proteins overexpressed in tumors", P_AAX28437; Patent: WO9914327-A2; filed September 10, 1998; Publication Date: March 25, 1999.</p>			
<p>Chen, et al., "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAX52234; Patent: WO9914328-A2; filed September 16, 1998; Publication Date: March 25, 1999.</p>			
<p>Ashkenazi, et al., "New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 and PRO1868, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy", P ACA58386; Patent: US2002192659-A1; filed July 10, 2001; Publication Date: December 19, 2002.</p>			
<p>Ashkenazi, et al., "New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, in generating probes and in tissue typing", P ACA60093; Patent: US2003003530-A1; filed July 11, 2001; Publication Date: January 2, 2003.</p>			
<p>Ashkenazi, et al., "Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in treating cancer and Alzheimer's disease", P ACA05431; Patent: US2003023054-A1; filed July 16, 2001; Publication Date: January 0, 2003.</p>			
EXAMINER	DATE CONSIDERED		


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b>		ATTY. DOCKET NO.:	SERIAL NO.:
		39780-16182C17	09/904,838
		<b>APPLICANT :</b> Ashkenazi, et al.	
<b>FILING DATE:</b> 7/13/01		<b>GROUP:</b> 1647	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<p>Ashkenazi, et al., "New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245) and genes encoding them, useful for detecting or treating e.g. hyperplasia, endometriosis, cancers, ischemia, coronary arterial disease or inflammations", P_ABX96110; Patent: US2002160374-A1; filed July 12, 2001; Publication Date: October 31, 2002.</p>			
<p>Ashkenazi, et al., "Isolated nucleic acid useful for e.g. treating pathological disorders encodes a secreted or transmembrane protein", P_ACAS58989; Patent: US2002146709-A1; filed July 18, 2001; Publication Date: October 10, 2002.</p>			
<p>Ashkenazi, et al., "Novel secreted and transmembrane polypeptides and polynucleotides encoding them useful for treating abnormal bleeding involved in gynecological diseases, skin disease and neurodegenerative diseases", P_ACD19736; Patent: US2003027143-A1; filed July 16, 2001; Publication Date: February 6, 2003.</p>			
<p>Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ACAS54901; Patent: US2003017463-A1; filed July 11, 2001; Publication Date: January 23, 2003.</p>			
<p>Ashkenazi, et al., "New genes and secreted and transmembrane polypeptides (e.g. PRO245 or PRO335), useful for treating or diagnosing e.g. Alzheimer's disease, cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia or strokes", P_ACD07493; Patent: US2002197671-A1; filed July 17, 2001; Publication Date: December 26, 2002.</p>			
<p>Ashkenazi, et al., "Novel secreted and transmembrane polypeptide for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptide, and as molecular weight markers", P_ACD23584; Patent: US2003064923-A1; filed July 13, 2001; Publication Date: April 3, 2003.</p>			
<p>Clark, et al., "The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A bioinformatics Assessment" AY358873; Genome Res. 13 (10), 2265-2270 (2003) direct submission submitted August 1, 2003.</p>			
<p>Botstein, et al., "Polypeptidic compositions and methods for the treatment of tumors", AX076929; Patent WO0105836-A 41, filed January 25, 2001.</p>			
<p>Ashkenazi, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", AX697522; Patent WO0104311-A 113, filed January 18, 2001.</p>			
<p>Wood, et al., "Secretory and transmembrane polypeptides and nucleic acid encoding the same", BD075461; Patent: JP2001516580-A 94, filed October 2, 2001.</p>			
<p>Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD172321; Patent: JP2002223786-A 94, filed August 13, 2002.</p>			
<p>Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD172640; Patent: JP2002238586-A 94, filed August 27, 2002.</p>			
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>		


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b>		ATTY. DOCKET NO.: 39780-16182C17	SERIAL NO.: 09/904,838
		<b>APPLICANT :</b> Ashkenazi, et al.	
		FILING DATE: 7/13/01	GROUP: 1647
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<p>Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD172959; Patent: JP2002238587-A 94, filed August 27, 2002.</p>			
<p>Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD173278; Patent: JP2002238588-A 94, filed August 27, 2002.</p>			
<p>Wood, et al., "Secreted and transmembrane polypeptides and nucleic acids encoding the same", BD175312; Patent: JP2002253280-A 94, filed September 10, 2002.</p>			
<p>Yashiro, et al., "Distinct transcriptional regulation and phylogenetic divergence of human LEFTY genes", NM_020997, <i>Genes Cells</i> 5 (5), pp. 343-357 (2000).</p>			
<p>Kosaki, et al., "Characterization and mutation analysis of human LETY A and LEFTY B, homologues of murine genes implicated in left/right axis development, NM_020997, <i>Am. J. Hum. Genet.</i> 64 (3), pp. 712-721 (1999).</p>			
<p>Strausberg, R., direct submission (April 8, 2002) to National Institutes of Health, Mammalian Gene Collection (MG), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590; BC027883.</p>			
<p>Ebner, et al., "Novel Nodal and Lefty polypeptides useful for diagnosing or treating cell growth and differentiation related disorders in humans, e.g. cancer, autoimmunity, arthritis and immunosuppression", P_AAD45128; Patent: US2002086351-A1; filed August 20, 1998; Publication Date: July 4, 2002.</p>			
<p>Ebner, et al., "New isolate human Nodal and Lefty polypeptides", P_AAX31925; Patent: WO9909198-A1; filed August 20, 1998; Publication Date: February 25, 1999.</p>			
<p>Birse, et al., "Isolated nucleic acid molecules encoding novel ovarian polypeptides, useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian cancer), immune disorders, cardiovascular disorders and neurological diseases", P_ABQ55009; Patent: WO200200677-A1; Filed June 7, 2001; Publication Date: January 3, 2002.</p>			
<p>Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ABUS4366; Patent: US2002132240-A1; filed July 18, 2001; Publication Date: September 19, 2002.</p>			
<p>Ashkenazi, et al., "New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245) and genes ecoding them, useful for detecting or treating e.g. hyperplasia, endometriosis, cancers, ischemia, coronary arterial disease or inflammations", P_ABUS4518; Patent: US2002160374-A1; Filed July 12, 2001; Publication Date: October 31, 2002.</p>			
<p>Ashkenazi, et al., "Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in chrososome and gene mapping, in generating antisense RNA and DNA, and in treating cancer and Alzheimer's disease", P_ABUS67364; Patent: US2003023054-A1; filed July 16, 2001; Publication Date: January 30, 2003.</p>			
EXAMINER	DATE CONSIDERED		


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  	<b>ATTY. DOCKET NO.:</b>	<b>SERIAL NO.:</b>
	39780-16182C17	09/904,838
	<b>APPLICANT :</b> Ashkenazi, et al.	
	<b>FILING DATE:</b> 7/13/01	<b>GROUP:</b> 1647
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
<p>Ashkenazi, et al., "New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, in generating probes and in tissue typing", P_ABUS71910; Patent: US2003003530-A1; filed July 11, 2001; Publication Date: January 2, 2003.</p>		
<p>Ashkenazi, et al., "New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or PRO1868, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy", P_ABUS71464; Patent: US2002192659-A1; filed July 10, 2001; Publication Date: December 19, 2002.</p>		
<p>Ashkenazi, et al., "New PRO polypeptides and nucleic acid molecules, useful in diagnosing or treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or Parkinson's disease", P_ABUS69641; Patent: US2003017463-A1; filed July 11, 2001; Publication Date: January 23, 2003.</p>		
<p>Ashkenazi, et al., "Isolated nucleic acid useful for e.g. treating pathological disorders encodes a secreted or transmembrane protein", P_ABUS71609; Patent: US2002146709-A1; filed July 18, 2001; Publication Date: October 10, 2002.</p>		
<p>Ashkenazi, et al., "New genes and secreted and transmembrane polypeptides (e.g. PRO245 or PRO335), useful for treating or diagnosing e.g. Alzheimer's disease, cancers, hemorrhage, rheumatoid arthritis, diabetes, cirrhosis, ischemia or strokes", P_ABO1793; Patent: US2002197671-A1; filed July 17, 2001; Publication Date: December 26, 2002.</p>		
<p>Ashkenazi, et al., "Novel secreted and transmembrane polypeptides and polynucleotides encoding them useful for treating abnormal bleeding involved in gynecological diseases, skin disease and neurodegenerative diseases", P_ABO14823; Patent: US2003027143-A1; filed July 16, 2001; Publication Date: February 6, 2003.</p>		
<p>Ashkenazi, et al., "Novel secreted and transmembrane polypeptide for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptide, and as molecular weight markers", P_ABO17574; Patent: US2003064923-A1; filed July 13, 2001; Publication Date: April 3, 2003.</p>		
<p>Ashkenazi, et al., "Novel isolated PRO polypeptides, e.g. PRO245 and PRO1868, useful for treating e.g. Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, cancer neuropathies, diabetes and psoriasis", P_ABO17513; Patent: US2003064367-A1, filed July 13, 2001; Publication Date: April 3, 2003.</p>		
<p>Ashkenazi, et al., "Novel secreted and transmembrane polypeptides for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptides, and as molecular weight markers", P_ABO14884; Patent: US2003036060-A1; filed July 12, 2001; Publication Date: February 20, 2003.</p>		
<p>Monahan, et al., "Assessing whether a patient is afflicted with ovarian cancer, useful comparing the expression level of a cancer marker in a sample from a patient and from a non cancer patient", P_ABC96362; Patent: WO200271928-A2; filed March 14, 2002; Publication Date: September 19, 2002.</p>		
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	<b>ATTY. DOCKET NO.:</b>	<b>SERIAL NO.:</b>
	39780-16182C17	09/904,838
	<b>APPLICANT :</b> Ashkenazi, et al.	
	<b>FILING DATE:</b> 7/13/01	<b>GROUP:</b> 1647
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
<p>Ebner, et al., "Novel Nodal and Lefty polypeptides useful for diagnosing or treating cell growth and differentiation related disorders in humans, e.g. cancer, autoimmunity, arthritis and immunosuppression", P_AAE28182; Patent: US2002086351-A1; filed August 20, 1998; Publication Date: July 4, 2002.</p>		
<p>Ashkenazi, et al., "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung squamous cell carcinoma) and Neurodegenerative diseases (e.g. Alzheimer's disease)", P_AAB80231; Patent: WO200104311-A1; filed February 22, 2000; Publication Date: January 18, 2001.</p>		
<p>Botstein, et al., "New antibody that binds to a PRO polypeptide, e.g. PRO187 and PRO533, useful for diagnosing and treating cancers", P_AAB68600; Patent: WO200105836-A1; filed December 20, 1999; Publication Date: January 25, 2001.</p>		
<p>Goddard, et al., "New isolated antibodies which bind to specific polypeptides used for diagnosis and treatment of neoplastic cell growth and proliferation", P_AAY88575; Patent: WO200015666-A2; filed September 8, 1999; Publication Date: March 23, 2000.</p>		
<p>Botstein, et al., "Antibodies against specific proteins overexpressed in tumors", P_AAY05287; Patent: WO9914327-A2; filed September 10, 1998; Publication Date: March 25, 1999.</p>		
<p>Ebner, et al., "New isolate human Nodal and Lefty polypeptides", P_AAY03850; Patent: WO9909198-A1; filed August 20, 1998; Publication Date: February 25, 1999.</p>		
<p>Chen, et al., "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAY13363; Patent: WO9914328-A2; filed September 16, 1998; Publication Date: March 25, 1999.</p>		
<p>Kosaki, et al, Direct submission (August 1, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza S230, Houston, TX 77030; AAD48144; Accession: AF081512.</p>		
<p>Strausberg, R., Direct submission (April 8, 2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590; AAH27883; Accession: BC027883.</p>		
<p>Kosaki, et al, Direct submission (August 3, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza S230, Houston, TX 77030; AAC33967; Accession: AF081507.</p>		
<p>Clark, et al., direct submission (August 1, 2003) Department of Bioinformatics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080; AAQ89232; Accession: AY358873.</p>		
<p>Kosaki, et al., "Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development", NP_066277; Accession: NM_020997; Am. J. Hum. Gen. 66, 712-721 (1999).</p>		
<p>Kosaki, et al., "Characterization and mutation analysis of human LEFTY A and LEFTY B, homologues of murine genes implicated in left-right axis development", Accession: 075610; Am. J. Hum. Gen. 66, 712-721 (1999).</p>		
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b> <small>DEC 04 2003</small>		<b>ATTY. DOCKET NO.:</b>	<b>SERIAL NO.:</b>
		39780-16182C17	09/904,838
		<b>APPLICANT :</b> Ashkenazi, et al.	
		<b>FILING DATE:</b> 7/13/01	<b>GROUP:</b> 1647
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<p>Celeste, et al., "New Purified bone morphogenic protein-17 and -18 (BMP-17 and BMP-18) polypeptides, useful or the induction of growth and/or differentiation of undifferentiated embryonic and stem cells", P_AAY17870; Patent: WO9929718-A2; filed November 17, 1998; Publication Date: June 17, 1999.</p>			
<p>Tabibzadeh, et al., "Inhibiting the activity of transforming growth factor (TGF) beta, for treating e.g. fibrosis, comprises contacting tissue expressing TGF beta with ebaF peptide or its analogue", P_AAU79519; Patent: WO200229105-A1; filed October 3, 2001; Publication Date: April 11, 2002; Accession: P_AAU79519</p>			
<p>Tabibzadeh, et al., "Inducing growth and enhancing survival of nervous tissue by contacting with endometrial bleeding associated factor protein", P_AAB19837; Patent: WO200066068; filed April 28, 2000; Publication Date: November 9, 2000; Accession: P_AAB19837.</p>			
<p>Ota, et al., "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs", P_AAB95157; Patent Number: EP1074617-A2, filed July 28, 2000; Publication Date: February 7, 2001; Accession: P_AAB95157.</p>			
<p>Celeste, et al., "New Purified bone morphogenic protein-17 and -18 (BMP-17 and BMP-18) polypeptides, useful or the induction of growth and/or differentiation of undifferentiated embryonic and stem cells", P_AAY17871; Patent: WO9929718-A2; filed November 17, 1998; Publicate Date: June 17, 1999; Accession: P_AAY17871.</p>			
<p>Kosaki, et al., direct submission (August 1, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza, S230, Houston, TX 77030; AAD48145; Accession: AF081513.</p>			
<p>Strausberg, R., direct submission (July 31, 2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590; AAH35718; Accession: BC035718.</p>			
<p>Bassi, et al., Direct submission (August 3, 1998) Department of Pathology, Baylor College of Medicine, One Baylor Plaza, S230, Houston, TX 77030; AAC32600; Accession: AF081511.</p>			
<p>Kothapalli, et al., "Detection of ebaF, a novel human gene of the transforming growth factor beta superfamily association of gene expression with endometrial bleeding", NP_003231; Accession: NM_003240; J. Clin. Invest. 99 (10), 2342-2350 (1997).</p>			
<p>Kothapalli, et al., "Detection of ebaF, a novel human gene of the transforming growth factor beta superfamily association of gene expression with endometrial bleeding", TGF4_HUMAN; Accession: 000292; 075611; J. Clin. Invest. 99 (10), 2342-2350 (1997).</p>			
<p>Isogai, et al., "direct submission (March 20, 2002) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan; BAC11556; Accession: AK075344.</p>			
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>   <b>PTO-1449</b> <b>DEC 04 2003</b> <small>PATENT &amp; TRADEMARK OFFICE</small>		<b>ATTY. DOCKET NO.:</b>	<b>SERIAL NO.:</b>
		39780-16182C17	09/904,838
		<b>APPLICANT :</b> Ashkenazi, et al.	
		<b>FILING DATE:</b> 7/13/01	<b>GROUP:</b> 1647
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<p>Tabibzadeh, et al., "Inhibiting the activity of transforming growth factor (TGF) beta, for treating e.g. fibrosis, comprises contacting tissue expressing TGF beta with ebaF peptide or its analogue", P_AAU79521; Patent: WO200229105-A1; filed October 3, 2001; Publication Date: April 11, 2002; Accession" P_AAU79521.</p>			
<p>Tabibzadeh, et al., "Inhibiting the activity of transforming growth factor (TGF) beta, for treating e.g. fibrosis, comprises contacting tissue expressing TGF beta with ebaF peptide or its analogue", P_AAU79520; Patent: WO200229105-A1; filed October 3, 2001; Publication Date: April 11, 2002; Accession: P_AAU79520.</p>			
<p>Wang, et al., "Treating a subject with a disorder resulting from insufficient insulin production, and inducing outgrowth of pancreatic cells, involves using a transforming growth factor beta therapeutic", P_AAU77104; Patent: WO200212336-A2; filed February 9, 2001; Publication Date: February 14, 2002; Accession: P_AAU77104.</p>			
<p>Weintraub, et al., "New mutant cystine knot growth factor proteins comprising one or more mutant subunits, useful for treating or preventing diseases e.g. hypothyroidism and thyroid cancer", P_AAY92013; Patent: WO200017360-A1; filed March 19, 1999; Publication Date: March 30, 2000; Accession: P_AAY92013.</p>			
<p>Tabibzadeh, et al., direct submission (December 9, 1996) Pathology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612; AAB53269; Accession: U81523.</p>			
<p>Edmonds, et al., "Novel polypeptides and polynucleotides of secreted proteins useful for treating various diseases such as multiple sclerosis, cancer, autoimmune diseases, osteoporosis, Alzheimer's disease and Parkinson's disease", P_AAU91323; Patent: WO200214358-A2; filed July 30, 2001; Publication Date: February 21, 2002; Accession: P_AAU91323.</p>			
<p>Edmonds, et al., "Novel secreted proteins and their uses", CAD29027; Patent: WO0214358-A1, filed February 21, 2002; Accession: AX392959.</p>			
<p>Birse, et al., "Isolated nucleic acid molecules encoding novel ovarian polypeptides, useful in the prevention, treatment and diagnosis of cancer (e.g. ovarian cancer), immune disorders cardiovascular disorders and neurological diseases", P_ABP41932; Patent: WO200200677-A1; filed June 7, 2001; Publication Date: January 3, 2002; Accession: P_ABP41932.</p>			
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.